Medullary thymic epithelial cells (mTECs) contribute to self-tolerance through the ectopic expression of tissue-specific antigens (TSAs) in the thymus ([@bib10]; [@bib2]; [@bib21]). This TSA expression in mTECs is largely dependent on autoimmune regulator (Aire), which is expressed in mature mTECs ([@bib13]; [@bib15]; [@bib21]). Through the recognition of TSAs, developing autoreactive T cells are either negatively selected from the pool of developing thymocytes or recruited into the regulatory T (T reg) cell lineage ([@bib19]; [@bib3]; [@bib11]; [@bib26]; [@bib28]; [@bib20]). The overall importance of this process is underscored by the development of a multi-organ autoimmune syndrome in patients or mice with defective *AIRE* expression ([@bib8]; [@bib23]; [@bib2]).

Although central tolerance provides protection against autoimmunity, this process also represents a challenge for anti-tumor immunity ([@bib18]; [@bib20]). Because many of the TSAs expressed in the thymus are also expressed in tumors, high-affinity effector T cells capable of recognizing tumor self-antigens may normally be deleted in the thymus ([@bib5]; [@bib7]; [@bib29]; [@bib30]). Transiently suppressing central tolerance by depleting mTECs or modulating *Aire* expression may provide a therapeutic window for the generation of T cells capable of recognizing tumor self-antigens. Many current cancer immune therapies rely on activating relatively weak tumor-specific T cell responses through modulating peripheral tolerance ([@bib27]; [@bib6]). In contrast, manipulation of central tolerance has the potential to increase the pool and affinity of effector T cells that can recognize and contribute to effective anti-tumor responses. Furthermore, such high-affinity, self-reactive T cells may be more resistant to peripheral tolerance mechanisms that typically restrain an anti-tumor response ([@bib27]). Thus, the development of methods that selectively and transiently deplete *Aire*-expressing mTECs may be an attractive method to enhance tumor-specific immune responses.

Previous work has identified agents that can inhibit the growth and development of TECs such as corticosteroids, cyclosporine, and some inflammatory cytokines ([@bib4]; [@bib12]). Despite their clear inhibitory effects on TECs, however, these agents do not appear to have selectivity for blocking mTEC development. Interestingly, recent studies have demonstrated a role for TNF family member pairs RANK--RANKL and CD40-CD40L in the embryological development of Aire^+^ mTECs ([@bib25]; [@bib1]; [@bib16]; [@bib24]). Recent work has also demonstrated that mTECs in particular have a relatively fast turnover in adult mice with an estimated half-life of ∼2 wk ([@bib13]; [@bib15]). Given these findings, we speculated that in vivo blockade of RANKL in adult hosts could both selectively and transiently inhibit the development and turnover of mTECs with potential to alter central T cell tolerance. To this end, we performed in vivo RANKL blockade in adult mice and investigated its effects on both TECs and developing thymocytes. We show that anti-RANKL treatment not only depleted mTECs but could also be used therapeutically to break central tolerance and, as a result, increase the generation of tumor-specific T cells.

RESULTS AND DISCUSSION
======================

Depletion of mTECs with RANKL blockade
--------------------------------------

The RANK--RANKL signaling pathway is important for mTEC development, but it remains unclear what impact perturbation of this pathway might have on the adult thymus. Previous work has linked the RANK--RANKL pathway to the development of *Aire*-expressing mTECs ([@bib25]; [@bib1]; [@bib16]; [@bib24]), and we hypothesized that treating mice with blocking anti-RANKL antibody would decrease Aire^+^ mTECs. We treated wild-type mice with either anti-RANKL or isotype control antibody for 2 wk and harvested their thymi for analysis. Interestingly, although mice treated with anti-RANKL showed only a modest loss of cortical thymic epithelial cell (cTEC) cellularity, they exhibited a severe depletion of \>80% of mTECs ([Fig. 1 A](#fig1){ref-type="fig"}). Using MHC II and Aire as markers of mTEC maturation ([@bib13]; [@bib15]), we further analyzed the immature mTEC^lo^ (MHC II^lo^ Aire^−^), intermediate mTEC^hi^ (MHC II^hi^ Aire^−^), and mature Aire^+^ mTEC subsets (MHC II^hi^ Aire^+^). The relative mTEC composition in anti-RANKL--treated mice revealed a substantial loss of Aire^+^ and mTEC^hi^ cells along with enrichment of the remaining mTEC^lo^ cells ([Fig. 1 B](#fig1){ref-type="fig"}). Although absolute numbers of mTECs were decreased across all mTEC subsets, mTEC depletion was mostly due to the loss of \>90% of all Aire^+^ and mTEC^hi^ cells ([Fig. 1 B](#fig1){ref-type="fig"}). Immunostaining revealed a slight decrease in the density of keratin-5^+^ (K5) cells in the medulla of anti-RANKL--treated mice, whereas Aire^+^ cells were nearly undetectable ([Fig. 1 C](#fig1){ref-type="fig"}). Importantly, staining for keratin-8 (K8) and K5 showed that the overall corticomedullary thymic architecture was preserved despite the loss of mature mTECs ([Fig. 1 C](#fig1){ref-type="fig"}). Furthermore, consistent with the loss of the Aire^+^ and mTEC^hi^ subsets, Aire-dependent TSA gene expression in sorted mTECs was decreased in anti-RANKL--treated mice ([Fig. 1 D](#fig1){ref-type="fig"}).

![**Selective depletion of mTECs with anti-RANKL blockade.** (A) Wild-type mice were treated for 2 wk with either isotype (gray) or anti-RANKL (αRANKL, blue) antibody, and absolute numbers of mTECs and cTECs were enumerated by flow cytometry. Bar graphs of total cell numbers are depicted by mean ± SEM. (B) Representative flow cytometry plots of mTECs in A showing relative composition of mTEC subsets. Values represent mean ± SEM. Bar graphs (right) of total cell numbers of each mTEC subset depicted by mean ± SEM. (C) Top panels show immunostaining for keratin-8 (green) and keratin-5 (red) on thymic sections, and bottom panels show immunostaining for keratin-5 (red) and Aire (green). Bars: (top) 500 µm; (bottom) 50 µm. (D) Gene expression analysis on mTECs sorted from wild-type mice treated with either isotype (gray) or anti-RANKL (blue) antibody. Results standardized to Cyclophilin A and normalized to isotype-treated mice with bars depicting mean ± SD. (E) Representative flow cytometry plots of thymocytes from antibody-treated wild-type mice. Values depict mean ± SD. Total thymocyte numbers (right) are indicated with each circle depicting an individual animal and bars showing the mean. (F) Flow cytometric analysis of Foxp3 staining in CD4 SP thymocytes from E. Plots (right) show percentage and number of thymic CD4^+^ Foxp3^+^ cells, with bars showing the mean. Data shown in [Fig. 1](#fig1){ref-type="fig"} is representative of two to four independent experiments containing three or more individual mice within each group. \*, P ≤ 0.05; \*\*\*, P ≤ 0.001, Student's *t* test.](JEM_20131889_Fig1){#fig1}

Next, we characterized the impact of anti-RANKL--mediated mTEC depletion on thymocyte selection. In the polyclonal T cell repertoire of wild-type mice treated with anti-RANKL, we observed a modest increase in frequencies of both CD4 single-positive (SP) and CD8 SP thymocytes, consistent with a lack of negative selection ([Fig. 1 E](#fig1){ref-type="fig"}). Importantly, anti-RANKL--treated mice showed only a slight reduction in the frequency of double-positive thymocytes while absolute numbers were maintained, confirming normal positive selection. In addition, total thymocyte numbers were also maintained in mice treated with anti-RANKL ([Fig. 1 E](#fig1){ref-type="fig"}). Furthermore, anti-RANKL--treated mice showed a 50% reduction of Foxp3^+^ T reg cells within the CD4 SP subset ([Fig. 1 F](#fig1){ref-type="fig"}).

Given the dramatic impact of RANKL blockade on mTECs, we sought to determine whether this effect could be reversed in the context of increased RANK signaling. Osteoprotegerin (OPG; Tnfrsf11b) is a soluble decoy receptor for RANKL and its role as a negative regulator of RANK signaling has been well described in bone physiology ([@bib17]). Interestingly, in sorted wild-type mTECs, OPG expression was up-regulated in MHC II^hi^ mTECs when compared with MHC II^lo^ mTECs ([Fig. 2 A](#fig2){ref-type="fig"}). To test whether OPG negatively regulates RANK--RANKL signaling in mTECs, we analyzed thymi from *OPG*^−/−^ mice. While cTEC cellularity was increased threefold in *OPG*^−/−^ mice, mTEC cellularity was increased by nearly 10-fold when compared with *OPG^+/+^* mice ([Fig. 2 B](#fig2){ref-type="fig"}). Although absolute numbers of all mTEC subsets were increased in *OPG*^−/−^ mice, we observed an enrichment of Aire^+^ mTECs and a proportional loss of the mTEC^lo^ subset ([Fig. 2 C](#fig2){ref-type="fig"}). Immunostaining of K8 and K5 showed that *OPG*^−/−^ thymi maintained their corticomedullary thymic architecture despite these changes in TEC cellularity and mTEC composition ([Fig. 2 D](#fig2){ref-type="fig"}).

![**Increased Aire^+^ mTECs in OPG^−/−^ mice.** (A) Quantitative PCR analysis of Aire and OPG gene expression in MHC II^lo^ and MHC II^hi^ mTECs sorted from wild-type B6 mice. Results standardized to Cyclophilin A and normalized to MHC II^lo^, with error bars depicting mean ± SD. (B) Absolute numbers of mTECs and cTECs in OPG^+/+^ (black) and OPG^−/−^ (red) mice were enumerated by flow cytometry. Bar graphs of total cell numbers are depicted by mean ± SEM. (C) Representative flow cytometry plots of mTECs in B showing relative composition of indicated mTEC subsets. Values depict mean ± SEM. Bar graphs (right) depict total cell numbers of each mTEC subset and indicate mean ± SEM. (D) Immunostaining for keratin-8 (green) and keratin-5 (red) on frozen thymic sections from OPG^+/+^ and OPG^−/−^ mice. Data are representative of at least three independent experiments with at least three mice per group. \*, P ≤ 0.05; \*\*, P ≤ 0.01; \*\*\*, P ≤ 0.001, Student's *t* test. Bars, 500 µm.](JEM_20131889_Fig2){#fig2}

Collectively, these data suggest that RANK--RANKL--OPG interactions regulate both TEC cellularity and mTEC maturation, and are particularly important for the induction of Aire^+^ mTECs. Furthermore, anti-RANKL treatment selectively targeted mature mTECs and altered negative selection without affecting the development of new thymocytes.

Regeneration of mTECs after withdrawal of anti-RANKL
----------------------------------------------------

We next examined the kinetics of mTEC recovery after withdrawal from anti-RANKL blockade. After a 2-wk treatment window, we harvested mice at 2-wk intervals and observed gradual recovery of the mTEC^hi^ and Aire^+^ subsets ([Fig. 3, A and B](#fig3){ref-type="fig"}). By 10 wk, we observed the complete recovery of all mTEC subsets and a normal level of *Aire* expression after anti-RANKL treatment ([Fig. 3 B](#fig3){ref-type="fig"}). Interestingly, the pattern of mTEC recovery appeared consistent with published reports of mTEC^lo^ cells giving rise to mTEC^hi^ cells before the induction of Aire^+^ mTECs ([Fig. 3 B](#fig3){ref-type="fig"}; [@bib13]; [@bib15]; [@bib25]). Notably, thymi from anti-RANKL-- and isotype-treated mice at 10 wk were indistinguishable by immunostaining ([Fig. 3 C](#fig3){ref-type="fig"}). Thus, anti-RANKL--mediated mTEC depletion is a transient phenomenon with return of normal thymic composition after withdrawal of antibody treatment.

![**Regeneration of mTECs after anti-RANKL withdrawal.** (A) Experimental layout for analysis of mTEC recovery after anti-RANKL withdrawal. Wild-type mice were treated for 1 wk with isotype or anti-RANKL (black arrows) and harvested at indicated time points (red arrows). Graph (bottom) depicts relative composition of mTEC^lo^ mTEC^hi^ and Aire^+^ mTECs at each time point in anti-RANKL--treated mice. Values represent mean ± SEM. (B) Representative flow cytometry plot of mTECs from each of the indicated time points from A. Values represent the frequency of Aire^+^ mTECs. (C) Immunostaining for keratin-8 (green) and keratin-5 (red) on thymic sections from isotype or anti-RANKL--treated mice harvested at 10 wk. Bars, 500 µm. Data shown is representative of at least two independent experiments with three to five mice per group.](JEM_20131889_Fig3){#fig3}

Manipulation of thymic negative selection with RANKL blockade
-------------------------------------------------------------

To further characterize the impact of anti-RANKL treatment on negative selection, we first used the *OT-II* CD4^+^ TCR *x RIP-mOVA* double transgenic mouse model. *RIP-mOVA* transgenic mice express a membrane form of OVA under the control of the rat insulin promoter which results in its expression in both the pancreatic islets and in mTECs ([@bib3]). When the *OT-II* CD4^+^ TCR transgenic line is crossed to the *RIP-mOVA* transgenic line, OVA-specific *OT-II* T cells are deleted in the thymus ([@bib3]). We treated both *OT-II* and *OT-II x RIP-mOVA* mice with either anti-RANKL or isotype control antibody and performed thymocyte analysis. Consistent with previous reports, *OT-II x RIP-mOVA* mice treated with control antibody showed a significant reduction in the proportions of CD4 SP thymocytes and also had decreased frequencies and numbers of *OT-II^+^* T cells ([Fig. 4, A and B](#fig4){ref-type="fig"}; [@bib3]). In contrast, thymocyte profiles of anti-RANKL--treated *OT-II x RIP-mOVA* mice were indistinguishable from that of *OT-II* mice, demonstrating that RANKL blockade prevented thymic deletion of *OT-II* T cells yet allowed their positive selection ([Fig. 4, A and B](#fig4){ref-type="fig"}). We also observed a loss of thymic T reg cell development in these mice, which suggested a loss of cognate antigen (OVA) expression from mTECs within the thymus ([Fig. 4 C](#fig4){ref-type="fig"}).

![**Anti-RANKL--mediated mTEC ablation leads to altered negative selection.** (A) *OT-II* and *OT-II x RIP-mOVA* mice were harvested after 2 wk of indicated antibody treatment. Percentages of CD4 SP (top) and OT-II clonotype-specific (bottom) thymocytes are shown. Values represent mean ± SD. (B) Quantification of OT-II clonotype-specific CD4 SP cells from A. Graph shows mean ± SEM. \*\*, P ≤ 0.01, Student's *t* test. (C) Representative histograms for Foxp3 staining in CD4 SP events from A. (D) Wild-type mice were treated with isotype or anti-RANKL antibody for 3 wk, immunized with P2 peptide, and then harvested 10 d later for tetramer analysis. Representative flow cytometry plots of CD4^+^ T cells are shown for each condition. Values indicate absolute numbers of CD44^+^ P2-I-A^b^--specific T cells. *IRBP*^−/−^ mice were included as positive controls. Each dot on the graph represents an individual mouse, bars show mean, and the dotted line represents the limit of detection. Data shown is representative of two to three independent experiments. \*, P ≤ 0.05, Mann-Whitney test.](JEM_20131889_Fig4){#fig4}

To expand these observations to the polyclonal T cell repertoire, we analyzed the development of Aire-dependent autoreactive T cells using a tetramer enrichment protocol. Previously, we had shown that T cells specific for the self-antigen interphotoreceptor retinoid-binding protein (IRBP) are deleted in thymus of *Aire^+/+^* mice, whereas these cells escape deletion in *Aire*^−/−^ mice and cause autoimmune uveitis ([@bib11]; [@bib28]). Through the use of an IRBP peptide class II tetramer, P2-I-A^b^, such autoreactive CD4^+^ T cells can be detected in *Aire*^−/−^ mice. Given both the severe depletion of Aire^+^ mTECs and the loss of thymic *IRBP* expression in anti-RANKL--treated mice, we hypothesized that P2-I-A^b^--specific T cells could be detected in treated mice. After treating wild-type mice with anti-RANKL antibody, we immunized mice with a MHC II--binding IRBP peptide epitope (P2) to expand T cells for detection. 10 d after immunization, lymph nodes and spleen were pooled for the enumeration of CD4^+^ P2-I-A^b^--specific T cells by flow cytometry. Consistent with the loss of Aire^+^ mTECs, tetramer analysis of anti-RANKL--treated mice revealed an expansion of CD4^+^ P2-I-A^b^--specific T cells ([Fig. 4 D](#fig4){ref-type="fig"}). Overall, these data show a clear defect in negative selection associated with the loss of Aire^+^ mTECs in anti-RANKL--treated mice.

Treatment with anti-RANKL enhances anti-tumor immunity
------------------------------------------------------

Given its ability to selectively block mTECs and central tolerance, we next sought to determine whether anti-RANKL treatment could be used to therapeutically enhance anti-tumor immunity. Previous work has shown that many tumor self-antigens are expressed by mTECs as TSAs, and that high-affinity T cells capable of recognizing these tumor self-antigens are efficiently deleted in the thymus ([@bib5]; [@bib29]; [@bib30]). To test whether anti-RANKL treatment could rescue tumor self-antigen--specific T cells from thymic deletion, we used the *TRP-1* CD4^+^ TCR transgenic mouse model which generates T cells specific for the melanoma antigen TRP-1 (Tyrp1; [@bib22]). TRP-1 is expressed in B16 melanoma cells, and *TRP-1* T cells are efficacious against established B16 melanoma tumors ([@bib22]). Importantly, mTECs endogenously express *TRP-1* in an Aire-dependent manner, such that TRP-1--specific T cells are deleted in the thymi of *Aire*-sufficient, *TRP-1*--sufficient hosts ([@bib22]; [@bib30]). Given the depletion of Aire^+^ mTECs and loss of thymic *TRP-1* expression in anti-RANKL--treated mice ([Fig. 1 D](#fig1){ref-type="fig"}), we hypothesized that anti-RANKL treatment could rescue *TRP-1* T cells from thymic deletion. We treated *RAG1*^−/−^ *x TRP-1* TCR transgenic mice with either anti-RANKL or control antibody and harvested their thymi and spleens for analysis. Consistent with previous reports, isotype-treated mice showed efficient deletion of CD4 SP T cells in the thymus ([Fig. 5 A](#fig5){ref-type="fig"}; [@bib22]; [@bib30]). In contrast, anti-RANKL treatment prevented deletion of CD4 SP cells and also resulted in a much higher percentage of Vβ14^+^ T cells ([Fig. 5, A and B](#fig5){ref-type="fig"}). Furthermore, *TRP-1* T cells were detectable in the spleens of anti-RANKL--treated mice and also expressed higher levels of the Vβ14 TCR ([Fig. 5, A and B](#fig5){ref-type="fig"}). In addition, qPCR analysis revealed a loss of *Tyrosinase* and *Tyrp1* expression in the ear skin of anti-RANKL--treated mice which appeared consistent with the destruction of melanocytes by *TRP-1* T cells ([Fig. 5 C](#fig5){ref-type="fig"}).

![**RANKL blockade increases anti-melanoma immune response.** (A and B) *RAG1*^−/−^ *x TRP-1* TCR Tg mice were treated with isotype or anti-RANKL antibody for 2 wk and thymus and spleen were harvested for analysis. Flow cytometry plots in A show percentage of CD4^+^ (top) and CD4-gated Vβ14^+^ (bottom) T cells. Bar graphs in B show quantification of data in A. Values represent mean ± SEM. \*, P ≤ 0.05; \*\*, P ≤ 0.01; \*\*\*, P ≤ 0.001, Student's *t* test. Data shown is representative of at least three independent experiments with *n* = 4--7 mice per group. (C) Ear skin from mice treated with isotype (gray) or anti-RANKL (blue) antibody was analyzed by qPCR for Tyrosinase and Tyrp1 expression. Results standardized to β2m and normalized to untreated B6 wild-type mice (black) with bars depicting mean ± SD. (D) Survival curves of *RAG1*^−/−^ *x TRP-1* TCR Tg mice inoculated with B16 melanoma after treatment with isotype (gray) or anti-RANKL (blue) antibody, *n* = 7--8 mice for each group. P ≤ 0.05, Log-rank test. Data shown is representative of four independent experiments. (E) Tumor sections from isotype or anti-RANKL--treated mice in D were immunostained for CD3 (pink) with DAPI counterstain (purple). Bars, 50 µm. Mean densities of CD3^+^ cells per tumor area are quantified on the right. Four sections were evaluated for each treatment group and 6 imaging fields were randomly scored from each section. Graphs depict mean ± SEM. \*, P ≤ 0.05, Student's *t* test. (F) *RAG1*^−/−^ *x TRP-1* TCR Tg mice were inoculated with B16 melanoma after treatment with isotype (gray) or anti-RANKL (blue) antibody. Mice were harvested at 21 d after tumor inoculation and tumor-infiltrating lymphocytes (TILs) were analyzed by flow cytometry. Graph depicts percentage of Foxp3^+^ CD25^+^ T reg cells among CD4^+^ T cells. Values represent mean ± SEM. \*\*\*, P ≤ 0.001, Student's *t* test. Data shown is *n* = 7--9 mice per group pooled from two independent experiments. (G) Survival curves of *RAG1*^−/−^ recipients inoculated with B16 melanoma after adoptive transfer of splenocytes from either anti-RANKL (blue)-- or isotype (gray)--treated *RAG1*^−/−^ *x TRP-1* TCR Tg mice, *n* = 10 mice for each group. P ≤ 0.001, Log-rank test. Data shown is representative of two independent experiments.](JEM_20131889_Fig5){#fig5}

Next, we challenged anti-RANKL--treated *RAG1*^−/−^ *x TRP-1* mice with B16 melanoma to determine whether a limited break in central tolerance could improve overall survival. We observed a statistically significant increase in the survival of anti-RANKL--treated mice compared with the isotype-treated cohort ([Fig. 5 D](#fig5){ref-type="fig"}). We also found evidence of an enhanced T cell response in anti-RANKL--treated mice by measuring CD3^+^ T cell infiltrates within the tumors of these mice ([Fig. 5 E](#fig5){ref-type="fig"}). Of note, given the overall increase in T reg cells in the spleen and tumors of anti-RANKL--treated mice, it appears unlikely that the survival benefit observed in *TRP-1* mice is due to differences in T reg cell numbers ([Fig. 5, B and F](#fig5){ref-type="fig"}). Furthermore, to exclude potential effects of anti-RANKL antibody on the tumor microenvironment, we performed adoptive transfer studies in which splenocytes from antibody-treated *RAG1*^−/−^ *x TRP-1* mice were transferred into *RAG1*^−/−^ mice. When challenged with B16 melanoma, recipients of splenocytes from anti-RANKL--treated donors again showed a statistically significant increase in survival ([Fig. 5 G](#fig5){ref-type="fig"}). Collectively, these data demonstrate that short-term, reversible RANKL blockade of mTEC development can be used to create a therapeutic window that allows tumor self-antigen--specific T cells to escape thymic deletion. Furthermore, the generation of these high-affinity tumor-specific T cells confers a survival benefit in a melanoma tumor model.

In conclusion, our findings provide strong evidence that mTECs can be selectively and therapeutically targeted by RANKL blockade in adult mice and that anti-RANKL can be used as an approach to enhance anti-tumor responses. To date, previous efforts on the therapeutic manipulation of TECs have shown global effects that involve both cTECs and mTECs and disrupt thymocyte development ([@bib12]). The selectivity for mTECs with anti-RANKL thus provides evidence that central tolerance can be transiently suppressed in adult hosts while maintaining T cell generation. Although autoimmunity is a dangerous potential consequence of this approach, the treatment may also be an attractive new method to help break tolerance for cancer immunotherapy. Interestingly, although we could detect an expansion of retina-specific T cells in anti-RANKL--treated mice, we did not observe development of spontaneous uveitis (unpublished data), suggesting that this brief window of central tolerance suppression was countered by peripheral tolerance mechanisms such as T reg cells which existed before treatment. Importantly, we find that the medullary epithelial compartment of the thymus recovers after withdrawal of anti-RANKL antibody and, thus, only a transient window of central tolerance suppression occurs. This window may be an attractive feature of this approach, especially if coupled with methods that preferentially expand tumor-specific T cells over pathogenic autoreactive T cells. Currently, there has been intense interest and progress in manipulating peripheral tolerance for immunotherapy ([@bib6]). Given our results, it will also be of interest to determine if a combination of methods that target both central and peripheral tolerance could further enhance anti-tumor immune responses. Finally, it is important to note that our results also have implications for patients in the clinical setting receiving denosumab, a humanized monoclonal antibody that blocks RANKL which is widely used in the treatment of osteoporosis in adults ([@bib9]). Further study will be needed in such patients regarding their susceptibility to autoimmunity and for other potential defects in central tolerance.

MATERIALS AND METHODS
=====================

### Mice.

C57BL/6, *B6.RAG1*^−/−^ *Tyrp1^B-w^ TRP-1 TCR* transgenic, and *B6.OPG*^−/−^ mice were purchased from The Jackson Laboratory. Mice were treated intraperitoneally with 100 µg anti-RANKL (IK22/5) or isotype control (2A3; Bio X Cell) antibody three times per week as stated in the text. *B6.OT-II*, *B6.RIP-mOVA*, and *B6.IRBP*^−/−^ mice were described previously ([@bib3]; [@bib11]). Mice were treated at 3--5 wk of age and harvested at time points indicated in the text. All mice were housed and bred in specific pathogen-free conditions in animal facilities at UCSF or UNC, Chapel Hill. Animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at UCSF or UNC, Chapel Hill.

### Quantitative PCR.

RNA was extracted from sorted mTECs using the RNeasy Micro Plus kit (QIAGEN) and cDNA was synthesized with the Invitrogen Superscript III kit. TaqMan gene expression assays (Applied Biosystems) were used for all targets.

### Histology and immunofluorescence.

Thymi were harvested and embedded in O.C.T. media (Tissue-Tek). 8-µm frozen thymic sections were fixed in 100% acetone, blocked, and stained for keratin-5, keratin-8 (Abcam), or Aire (eBioscience). Secondary antibodies were purchased from Invitrogen. Thymic sections were visualized using a widefield microscope (Apotome; Carl Zeiss). For tumor immunostaining, tumors were harvested and fixed in 10% formalin as previously described ([@bib30]). Fixed tumors were embedded in paraffin and sectioned for staining with anti-CD3 antibody and counterstained with DAPI. Tumor sections were visualized using a fluorescent microscope (BX60; Olympus) and analyzed using ImageJ software (National Institutes of Health).

### Flow cytometry.

TECs were isolated as previously described ([@bib14]). In brief, thymi were minced and digested with DNase I and Liberase TM (Roche) before gradient centrifugation with Percoll PLUS (GE Healthcare). Enriched stromal cells were stained with the indicated surface marker antibodies (BioLegend). mTECs were defined as CD45^−^, EpCAM^+^, MHC II^+^, Ly51^−^ events and cTECs were defined as CD45^−^, EpCAM^+^, MHC II^+^, Ly51^+^ events. For lymphocyte staining, all surface marker antibodies were obtained from BioLegend. For intracellular staining, cells were stained using the Foxp3 Staining Buffer Set and stained with anti-Foxp3 or anti-Aire (eBioscience). All data were collected using a flow cytometer (LSR II; BD) and analyzed with either FlowJo software (Tree Star) or FACS Diva (BD). Cell sorting was performed using a FACS Aria III cell sorter (BD).

### IRBP P2 peptide immunization and tetramer analysis.

Mice were immunized with 100 µg P2 peptide (IRBP; aa 271--290) emulsified in complete Freund's adjuvant as described previously ([@bib28]). Tetramer analysis was performed on pooled lymph nodes and spleen from treated mice 10 d after immunization. P2-I-A^b^ tetramer was generated by the National Institutes of Health Tetramer Core Facility, and tetramer staining was performed as described previously ([@bib28]). After tetramer enrichment, cells were stained with antibodies for flow cytometry, and counting beads (Invitrogen) were used to enumerate tetramer^+^ cells.

### B16 melanoma tumor challenge.

*B6.RAG1*^−/−^*TRP-1 TCR* transgenic mice were injected subcutaneously in the left flank with 1.0 × 10^5^ B16 melanoma cells. For adoptive transfer studies, spleens from donor mice were pooled and CD25-depleted before transfer into *B6.RAG1*^−/−^ hosts. Recipient mice were inoculated with 7.5 × 10^4^ B16 melanoma cells 7 d after transfer. Tumor growth was monitored by taking measurements of length (*L*) and width (*W*), and tumor volume was calculated as LW^2^/2. For generation of survival curves, death was defined as tumor size \>1,000 mm^3^.

### Statistical analysis.

Statistical analysis was performed using Prism 6.0 (GraphPad Software). Mann-Whitney Rank sum testing was performed on tetramer analysis. Student's *t* test was performed for TEC and lymphocyte analyses. Log-rank test was performed for Kaplan-Meier survival curves.
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